DISCLOSURE OF A MATERIAL DEVELOPMENT->EPGL & Coope
Post# of 29
Posted On: 10/19/2014 5:42:19 PM
DISCLOSURE OF A MATERIAL DEVELOPMENT->EPGL & CooperVision
https://www.otciq.com/otciq/ajax/showFinancia...?id=125904
Exclusive Development Agreement Signed with CooperVision, Inc., a Division of The Cooper Companies, Inc. (COO, NYSE)
EP Global Communications, Inc. (EPGL) and CooperVision, Inc. (CooperVision) have signed an exclusive Development Agreement for advanced ophthalmic and medical technologies. CooperVision is a market leader in the manufacturing and marketing of contact lenses. The Cooper Companies recently completed the acquisition of Sauflon Pharmaceuticals Limited for approximately $1.2 Billion Dollars.
Disclosure to Our Shareholders
Without identifying proprietary plans or specific technologies under development, the following general information is now hereby publicly disclosed to our shareholders:
Material Elements for Shareholders and Exclusivity
1. CooperVision has secured the exclusive right to co-develop EPGL advanced technologies of its choosing, with ownership of resulting intellectual property to be allocated in accordance with inventorships. EPGL has agreed to work exclusively with CooperVision in the ophthalmic and medical field to develop selected advanced technologies, granting CooperVision exclusive options to license or outright purchase EPGL’s rights to such
technologies. Under the Agreement, CooperVision will fund the co-development, prototyping, manufacturing and marketing of such technologies selected by CooperVision
and negotiated project by project. This Development Agreement is on-going.
2. The companies are currently working on selection of technologies, prototyping, andsecuring intellectual property rights to the same.
3. This Development Agreement is a highly advantageous relationship for our shareholders because of the significant global resources that CooperVision brings to the table as a very
respected leader in the field of contact lens manufacturing. Under the terms of the Development Agreement, revenues from successful development of new products with CooperVision, will result from outright purchase of EPGL technologies and/or on-going
share of sales revenues as negotiated between the companies.
About The Cooper Companies
The Cooper Companies, Inc. ("Cooper"
is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women's health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has approximately 9,000 employees with
products sold in over 100 countries. For more information, please visit www.coopercos.com
Interested investors may confirm the above disclosed information with The Cooper
Companies Investor Relations.
CONTACT: Kim Duncan
Senior Director, Investor Relations
ir@cooperco.com
925-460-3663
https://www.otciq.com/otciq/ajax/showFinancia...?id=125904
https://www.otciq.com/otciq/ajax/showFinancia...?id=125904
Exclusive Development Agreement Signed with CooperVision, Inc., a Division of The Cooper Companies, Inc. (COO, NYSE)
EP Global Communications, Inc. (EPGL) and CooperVision, Inc. (CooperVision) have signed an exclusive Development Agreement for advanced ophthalmic and medical technologies. CooperVision is a market leader in the manufacturing and marketing of contact lenses. The Cooper Companies recently completed the acquisition of Sauflon Pharmaceuticals Limited for approximately $1.2 Billion Dollars.
Disclosure to Our Shareholders
Without identifying proprietary plans or specific technologies under development, the following general information is now hereby publicly disclosed to our shareholders:
Material Elements for Shareholders and Exclusivity
1. CooperVision has secured the exclusive right to co-develop EPGL advanced technologies of its choosing, with ownership of resulting intellectual property to be allocated in accordance with inventorships. EPGL has agreed to work exclusively with CooperVision in the ophthalmic and medical field to develop selected advanced technologies, granting CooperVision exclusive options to license or outright purchase EPGL’s rights to such
technologies. Under the Agreement, CooperVision will fund the co-development, prototyping, manufacturing and marketing of such technologies selected by CooperVision
and negotiated project by project. This Development Agreement is on-going.
2. The companies are currently working on selection of technologies, prototyping, andsecuring intellectual property rights to the same.
3. This Development Agreement is a highly advantageous relationship for our shareholders because of the significant global resources that CooperVision brings to the table as a very
respected leader in the field of contact lens manufacturing. Under the terms of the Development Agreement, revenues from successful development of new products with CooperVision, will result from outright purchase of EPGL technologies and/or on-going
share of sales revenues as negotiated between the companies.
About The Cooper Companies
The Cooper Companies, Inc. ("Cooper"
is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women's health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has approximately 9,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com
Interested investors may confirm the above disclosed information with The Cooper
Companies Investor Relations.
CONTACT: Kim Duncan
Senior Director, Investor Relations
ir@cooperco.com
925-460-3663
https://www.otciq.com/otciq/ajax/showFinancia...?id=125904
(0)
(0)